Rising Geriatric Population Base All around the Globe is one of the Major Factors Fostering the Growth of the Mild Cognitive Impairment (MCI) Treatment Market

 

Patients suffering from mild cognitive impairment are at high risk of developing dementia. In patients, over and above 60 years, the prevalence rate of mild cognitive impairment is 12% to 18%, as indicated by various international studies. The prevalence of mild cognitive impairment among individuals living in long-term care settings varies from 5% to 10%. The stage of mild cognitive impairment can be the early stage to developing neurodegenerative diseases and Alzheimer disease.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-mild-cognitive-impairment-mci-treatment-market

The global mild cognitive impairment (MCI) treatment market is expected to reach USD 1,48,373.70 thousand by 2029 from USD 76,449.41 thousand in 2021, growing at a CAGR of 8.7% in the forecast period of 2022 to 2029. Rising prevalence of air pollution in combination with ever-rising geriatric population base is bolstering the growth of the market. Further, growing awareness among people regarding available treatment options is carving the way for the market to boom over the forecast period. Also, increasing expenditure pertaining to the number of research and development activities in combination with surging number of clinical trials is carving the way for the market to boom over the forecast period.

Mild Cognitive Impairment (MCI) Treatment Market

Increasing prevalence rate of air pollution is expected to drive the market's growth rate

Air pollution, as a result of innumerable reasons, impacts the cognitive functioning in the individuals. Air pollution is unsafe and is regarded at the cause of many health problems. Air pollutants pose severe health risks and can be fatal even in small amounts. According to the Journal of Climate and Atmospheric Science article, in June 2020, above the WHO air quality guidelines, more than 50 percent of the world’s population was exposed to increasing air pollution.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2020

Historic Years

2019 (Customizable to 2013-2018)

Quantitative Units

Revenue in USD Thousand, Volumes in Units, Pricing in USD

Segments Covered

Disease Type (Amnestic MCI, Non-Amnestic MCI), Treatment Type (Medications, Therapy), Route Of Administration (Oral, Parenteral, Others), Drug Type (Branded, Generics), Gender Type (Male, Female), Age Type (Child, Adult, Geriatric), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Pfizer Inc. (U.S.), F. Hoffman La Roche Ltd (Switzerland), Novartis AG (Switzerland), Accord UK Ltd (U.K.),, Dr. Reddy’s laboratories Ltd (India), Hikma Pharmaceuticals PLC (U.K.), Viatris Inc. (U.S.), Eisai. Co. Ltd. (Japan), Sun Pharmaceuticals ltd. (India), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Mallinckrodt (U.K.), AstraZeneca (U.K.), Cipla Inc. (India), Takeda Pharmaceutical Company Limited (Japan), Allergan (Ireland), Lupin (India), Jubilant Pharmova Limited (India), Lannett (U.S.), Aurobindo Pharma (India), UCB S.A. (Belgium), and WOCKHARDT (India) among others            

Data Points Covered in the Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The global mild cognitive impairment (MCI) treatment market is categorized into eight notable segments based on disease type, treatment type, route of administration, drug type, gender type, age, distribution, and end users.

  • Based on disease type, the global mild cognitive impairment (MCI) treatment market is segmented into amnestic MCI and non-amnestic MCI. In 2022, the amnestic MCI segment is expected to dominate the global mild cognitive impairment (MCI) treatment market a share of 67.55% due to the increase in the older population across the globe.
  • Based on treatment type, the global mild cognitive impairment (MCI) treatment market is segmented into medication and therapy. In 2022, the medication segment is expected to dominate the global mild cognitive impairment (MCI) treatment market with a share of 76.24% due to its immediate and effective impact on MCI symptoms.

Medication is expected to dominate the treatment type segment of the global mild cognitive impairment (MCI) treatment market

In 2022, the medication is set to dominate the market. This is because of the rising number of drug trials and drug delivery processes in combination with increased expenditure towards research and development proficiencies. Expansion of over-the-counter facilities is also creating a lucrative scope for the growth of the market.

  • Based on route of administration, the global mild cognitive impairment (MCI) treatment market is segmented into oral and parenteral, and others. In 2022, the oral segment is expected to dominate the global mild cognitive impairment (MCI) treatment market with the share of 49.65% due to the non-invasive, high patient compliance, convenience handling, and not requiring any specific sterile conditions.

Oral is expected to dominate the route of administration segment of the global mild cognitive impairment (MCI) treatment market

Oral route of administration is the most convenient mode. Drug delivery via oral mode or route of administration is not a complex process. Most of the medications can be consumed via oral mode, by all the genders and in all the age categories. This is why it is dominating the route of administration segment.

  • Based on drug type, the global mild cognitive impairment (MCI) treatment market is segmented into branded and generics. In 2022, the generics segment is expected to dominate the global mild cognitive impairment (MCI) treatment market with a share of 81.73% is due to the cost-effectiveness compared to branded drugs.
  • Based on gender, the global mild cognitive impairment (MCI) treatment market is segmented into male and female. In 2022, the male segment is expected to dominate the global mild cognitive impairment (MCI) treatment market with a share of 54.55% due to a surge in mental health complications observed in the male population.
  • Based on age, the global mild cognitive impairment (MCI) treatment market is segmented into child, adult, and geriatric. In 2022, the geriatric segment is expected to dominate the global mild cognitive impairment (MCI) treatment market with the share of 60.79% due to a surge in vulnerable older people population with the highest rate of increase in the Asian region.
  • Based on end users, the global mild cognitive impairment (MCI) treatment market is segmented into hospitals, specialty clinics, homecare, and others. In 2022, the hospital is expected to dominate in the global mild cognitive impairment (MCI) treatment market with the share of 60.29% due to increased awareness regarding better and more effective treatment during hospital stays.
  • Based on distribution type, the global mild cognitive impairment (MCI) treatment market is segmented into hospital pharmacies, retail pharmacy. In 2022, the hospital pharmacy is expected to dominate in the global mild cognitive impairment (MCI) treatment market with the share of 57.39% due to increased interaction with certified prescribers and health professionals to use antipsychotic drugs and guaranteed payment. 

Major Players

Data Bridge Market Research recognizes the following companies as the major advanced wound care market players in advanced wound care market are Pfizer Inc. (U.S.), AstraZeneca (U.K.), Dr. Reddy’s Laboratories Ltd. (U.K.), Aurobindo Pharma Limited (U.K.), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), AbbVie (U.S.), and Hikma Pharmaceuticals PLC (U.K.)

Mild Cognitive Impairment (MCI) Treatment Market

Market Development  

  • In July 2021, FDA approved Biogen Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway. Aduhelm is an amyloid beta-directed immunizer used to treat Alzheimer's sickness. Aduhelm is endorsed under the Accelerated Approval pathway, which furnishes patients with a genuine illness prior admittance to drugs when there is an assumption for clinical advantage notwithstanding some vulnerability about the clinical advantage.
  • In August 2021, AbbVie entered into a collaboration to access Mission’s expertise in deubiquitinating enzymes (DUBs). Under the details of the arrangement, the two players will work together during the research stage to recognize explicit DUBs and find appropriate mixtures. AbbVie will then, have the choice to acquire restrictive freedoms to create and popularize DUB inhibitors against up to four chose targets.
  • In December 2020, Novartis AG entered into an agreement to acquire Cadent Therapeutics. Novartis' neuroscience portfolio includes two additional clinical-stage initiatives, one for schizophrenia and the other for movement disorders. Novartis has gone into a conclusive consent to obtain all of the capital supply of US-based neuroscience organization Cadent Therapeutics for a complete possible consideration of up to $770m. Under the arrangement, Cadent will get a forthright installment of $210m and is qualified for achievement installments of up to $560m.

Regional Analysis

Geographically, the countries covered in the lung transplant therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in advanced wound care market during the forecast period 2022 - 2029

In 2022, North America is expected to dominate the mild cognitive impairment (MCI) treatment market because of its latest advanced technology and inventions in the healthcare sector. North America will continue to dominate the market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and launch of new products in this region. Additionally, the increasing number of cases of chronic wounds and the rising geriatric population are expected to further enhance the market's growth rate in this region. 

Asia-Pacific is estimated to be the fastest growing region in advanced wound care market the forecast period 2022 - 2029

Asia-Pacific is expected to grow during the forecast period due to the presence of major market players and rapid development of medical facilities in emerging economies in this region. In addition to this, rising healthcare expenditure and increasing per-capita income are expected to propel the market's growth rate in this region.

COVID-19 Impact Analysis

The outbreak of COVID-19 largely impacted the healthcare industry. The mild cognitive impairment (MCI) treatment market was, however significantly affected by it.  The imposition of the lockdown and social distancing restrictions by the government put a halt on the healthcare procedures and surgeries. The pandemic led to the utilization of resources towards meeting the demand arising out of COVID-19 emergencies. Stifling business growth and suspensions of new developments also limited the industry's expansion.

On the other hand, there has been a decline in COVID-19 patients worldwide, which will result in increased health care services. Moreover, the restrictions and measures are likely to relax, which will help market to witness a slight increment, as the manufacturers are focusing on various developments and innovations, market trends, and other expansion strategies.

For more detailed information about the mild cognitive impairment (MCI) treatment market report, click here – https://www.databridgemarketresearch.com/reports/global-mild-cognitive-impairment-mci-treatment-market